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be averted. ConClusions: Price elasticity estimates are greater than previous 
studies in Greece and consistent with literature internationally, while income 
elasticity estimates are far greater. With cigarettes regarded as a luxury good, a 
great opportunity is presented for decison makers to counter smoking. Increased 
taxation, along with focused antismoking campaigns, law reinforcement (to ensure 
compliance with smoking bans) and intensive control for smuggling could inflict 
a massive blow to the tobacco epidemic in Greece.
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objeCtives: COPD is the third leading cause of death with increasing mortality 
while other chronic condition mortality rates are decreasing. This may be due to 
the fact that COPD is a complex chronic condition with a complicated diagnosis 
and treatment guideline in an aging patient population with increasing comor-
bid conditions. The objective of this study was to understand the prevalence of 
comorbid conditions among COPD patients in the US. Methods: A retrospective 
database analysis was conducted using Marketscan Commercial and Medicare 
Supplement Data from year 1/1/2010 to 12/31/2011. Patients were included if they 
had continuous medical and pharmacy benefits coverage for at least 12 months 
after their first COPD diagnosis defined as primary or ancillary ICD-9 codes of 
491.xx, 492.xx, or 496.xx and were between the ages of 40 and 90 years old at the 
time of diagnosis. Univariate descriptive analyses were conducted to quantify 
comorbid disease prevalence. Results: Among the selected patients (n= 231,827), 
95.1% (n= 220,519) had medical claims (ICD-9 codes) for diagnoses beyond COPD 
within 12 months of their COPD diagnosis. The majority of patients were over 65 
years old (61.4%, n= 135,366). Over 60% (n= 130,325) of the patients had more than 
3 comorbid conditions. The most common were hypertension (64.9%, n= 143,189) 
(ICD-9 codes 401.xx-405.xx, 415, 416, 416.8, 459.1x and 459.3x), hyperlipidemia 
(46.5%,n= 102,498) (ICD-9 code 272.x), diabetes (27.8%, n= 61,225) (ICD-9 code 249.xx, 
250.xx, 253.5, 271.4, 357.2, 588.1, 790.29), coronary artery disease (27.4%, n= 60,364) 
(ICD-9 code 414.0x, 414.3, 414.4), and asthma (22.7%, n= 50,113) (ICD-9 code 493.
xx). ConClusions: Our results show the significant prevalence of comorbid con-
ditions among COPD patients. Further research on comorbid conditions impacting 
COPD patient treatment adherence, COPD pathogenic pathways and worsening 
overall prognosis are necessary. More evidence is required to estimate the role of 
comorbidities in COPD.
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objeCtives: To examine the burden of illness of diagnosed obesity in the U.S. veteran 
population. Methods: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEPT2012). 
Patients diagnosed with obesity were identified (International Classification of 
Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 278.xx) with 
the first diagnosis date designated as the index date. A group of patients without 
obesity but with the same age, region, gender and index year were identified and 
matched by baseline Charlson Comorbidity Index as a comparator group. The index 
date for the comparator group was randomly chosen to reduce selection bias. Patients 
in both groups were required to be at least 18 years old, and have 1 year of continu-
ous medical and pharmacy benefits before and after the index date. Study outcomes, 
including health care costs and utilizations, were compared between the disease 
and comparator groups by using 1:1 propensity score matching. Results: A total 
of 1,525,218 patients were identified for the obesity and comparison cohorts. After 
applying 1:1 matching, a total of 634,257 of patients were included in each group, and 
the baseline demographic and clinical characteristics were balanced. The obesity 
cohort had higher percentages of health care utilizations for inpatient (6.21% vs. 
2.92%, p< 0.01), emergency room (11.96% vs. 7.28%, p< 0.01), physician office (99.84% vs. 
60.12%, p< 0.01), outpatient (99.86% vs. 60.85%, p< 0.01), and pharmacy visits (89.01% 
vs. 61.71%, p< 0.01) than the comparator group. Patients diagnosed with obesity 
also incurred higher expenditures in inpatient ($1,812 vs. $875, p< 0.01), emergency 
room ($117 vs. $69, p< 0.01), physician office ($2,936 vs. $1,436, p< 0.01), outpatient 
($3,288 vs. $1,621) and pharmacy visits ($641 vs. $423, p< 0.01) compared to non-obese 
patients. ConClusions: Study results suggest that patients diagnosed with obesity 
incurred significantly higher costs and utilizations than non-obese patients.
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objeCtives: To compare clinical efficacy and safety of orphan drug deferasirox 
(DSX) versus deferoxamine (DFO) in the treatment of paediatric patients (age ≤ 18 
years) with iron overload from repeated blood transfusions. The underlying con-
ditions requiring transfusion included beta-thalassaemia, sickle cell disease and 
other congenital and acquired anaemias (myelodysplastic syndromes, Diamond-
Blackfan syndrome, aplastic anaemia and other very rare anaemias). Methods: 
We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled 
trials (RCTs) published up to April 2012. The review was conducted in accordance 
ability of prescription of asthma medications, there appears to be an unmet need 
and further research is necessary.
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objeCtives: To evaluate, compare, and assess the quality of the studies on the cost-
effectiveness of enhanced management (either as adjunct to usual care or alone) 
vs.usual care alone or none at all. Methods: Scientific databases (ScienceDirect, 
Wiley Online Library, (EbscoHost – MEDLINE, CINAHL, PSYInfo), (OvidSP – EMBASE, 
MEDLINE), and Scopus) were searched for published journal articles in English lan-
guage from year 1990 to 2012, using the search terms “asthma AND (intervene OR 
manage) AND (pharmacoeconomics OR economic evaluation OR cost effectiveness OR 
cost benefit OR cost utility)”. Hand search was done for local publishings. Only studies 
with full economic evaluation on enhanced management (either as adjunct to usual 
care or alone) were included. Selected studies were data abstracted and assessed for 
their quality of economic evaluation using the Quality of Health Economic Studies 
(QHES) instrument, and quality of evidence. Results: A total of 14 studies were 
included. There were three distinct modes reviewed: environmental control, self-
management, education. Most of the enhanced managements were found to be cost-
effective with ICER ranged from dominant to $26700.00 per unit of outcome. Overall, 
the mean score of QHES was 76.69% (SD 9.26). For the quality of evidence, ‘clinical 
effect sizes, adverse events & complication’, baseline clinical data, resourse use, and 
costs components were ranked mainly 1 or 2 (best or nearly best) in all studies. For 
‘utilities’ component, one study ranked 5 because it used visual analogue scale to 
obtain patient preference values. ConClusions: Despite the low qualities of the 
reviewed studies, it overall suggests that enhanced management (either as adjunct 
to usual care or alone) is mostly cost-effective than the usual care or none at all; 
environmental control is considered the most cost-effective, and there is also strong 
evidence for self-management, but provided the mode of it is made available, afford-
able, and accessible then this shall be worth to be adapted in one’s setting.
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objeCtives: Economic evaluation of the change in market dynamics of a sample 
ProductA1 through its inclusion in Therapeutic Equivalence Band (TEB) (with products 
B2 and C3) between 2010 and 2012 in Turkish health care system. Methods: IMS 
Dataview was analyzed for 2010-2012 unit sales values (market entry timeline for 
products A, B, C is 2006, 2009 and 2009, respectively) in the TEB. IMS Medical Index is 
used for estimating prescription data for the corresponding products. Assumptions on 
median patient adherence (receipt of prescribed treatment in pharmacy) are applied 
to prescription data in order to calculate unit sales (prediction). Deviation calcu-
lations and sensitivity analysis on market dynamics were performed in Microsoft 
Excel-2007. Results: Deviations between unit sales predictions and realizations 
for products A, B and C occurred as +11.48%, -5.41% and -20.85% in 2010, -10.16%, 
+8.14% and -53.87% in 2011 and -31.89%, +28.92% and -67.76% in 2012 respectively. 
Negative deviation values indicate that receipt of prescription cannot be transformed 
to receipt of the prescribed product in pharmacy, however positive deviation values 
correspond to receipt of a product in pharmacy which is different from the content of 
the prescription. ConClusions: The TEB system allows receipt of a different product 
than prescription. This study shows alteration of market dynamics in pharmacy as a 
change from prescribed inhaler option (as negative deviation value), which is linked 
to receipt of another inhaler option (as a positive deviation value) within the same 
TEB. Real life data may be collected for further analysis of TEB system in dynamics 
of corresponding market. 1Originator treatment in TEB-Novartis-Budesonide(400m
cg)&Formoterol(12mcg), 2Second treatment in TEB-Bilim Pharma, 3Third treatment 
in TEB-Abdi Ibrahim Pharma.
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objeCtives: Greece was long reported to show a smoking prevalence over 40% on 
adult population, as efforts to constrain smoking were rather ineffective. Following 
a sharp fall in cigarette consumption for 2012, our objective is to assess smokers’ 
sensitivity to cigarette price and consumer income changes as well as to project 
health benefits of an additional tax increase. Methods: Analysis includes the 
conventional model of demand, the myopic addiction model and the rational 
addiction model. Cigarette consumption for the period 1994-2012 was the depend-
ent variable with Weighted Average Price as a proxy for cigarette price, GDP as a 
proxy for consumer income and dummy variables reflecting smoking restrictions 
and antismoking campaigns. Values were computed to natural logarithms and 
regression was performed. Then, 4 scenarios of tax increase were distinguished in 
order to calculate potential health benefits. Results: Addiction models are una-
ble to provide statistically significant information following a nearly 23.5% drop 
in consumption during 2012. Short-run price elasticity is estimated at -0.441 and 
short-run income elasticity is estimated at 1.040. Antismoking campaigns were 
found to have a statistically significant impact on consumption. Results indicate 
that, depending on the level of tax increase, annual per capita consumption could 
fall by up to 607.99 cigarettes; tax revenue could rise by at least € 39 million, while 
up to 595,866 smokers could quit and up to 2,696 smoking related deaths could 
